Pulmonary Hypertension Institutional Registry (RIHP)

August 6, 2019 updated by: CRISTINA MARIA ELIZONDO, Hospital Italiano de Buenos Aires

Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires

The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.

Study Overview

Status

Withdrawn

Conditions

Detailed Description

The Institutional Registry of Pulmonary Hypertension includes patients prospectively with incident pulmonary hypertension, and excludes type II Pulmonary Hypertension. It also includes prevalent cases from our HMO who had diagnosis prior the beginning of the registry.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, 1181
        • Hospital Italiano de Buenos Aires

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults 17 yo or older, Any type of Pulmonary Hypertension except type II

Description

Inclusion Criteria:

  • More 17
  • Pulmonary Hypertension
  • Systolic Pulmonary Pressure >40 mmhg measured in a doppler echocardiogram,
  • Systolic artery pressure <25 in a pulmonary angiography

Exclusion Criteria:

  • Non accept to participate
  • Pulmonary Hypertension type II (Left cardiac disease)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary hypertension prevalence and incidence
Time Frame: 1 year
The main goal is to describe Pulmonary hypertension prevalence and incidence in our community as well as depict its risk factors, symptoms, prognosis and treatment response.
1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
Mortality rate
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Italiano de Buenos Aires

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Anticipated)

December 1, 2020

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

June 16, 2011

First Submitted That Met QC Criteria

December 26, 2011

First Posted (Estimate)

December 29, 2011

Study Record Updates

Last Update Posted (Actual)

August 7, 2019

Last Update Submitted That Met QC Criteria

August 6, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1487

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Death

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe